[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hormones\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hormones":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,106,147,168,195,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100632821","binaural-beat-music-virtual-reality-and-hormones-in-childbirth-100632821",false,"NCT07518667","Binaural Beat Music, Virtual Reality, and Hormones in Childbirth","The Effect of Binaural Rhythm-Supported Music and Virtual Reality Experience on Labor Pain and Hormones","VR","Inclusion Criteria:\n\n* Able to speak Turkish and communicate verbally\n* No hearing or visual impairments\n* The pregnancy is at term (37-42 weeks of gestation) and labor has begun\n* Single fetus with cephalic presentation\n* No chronic disease\n* Not taking hormone therapy\n* Pregnant women who do not have any obstetric risks and are expected to give birth normally\n\nExclusion Criteria:\n\n* Diagnosed with risky pregnancy\n* Complications during birth\n* Those with vision and hearing problems\n* Any pharmacological pain-reducing method applied\n* Cesarean section planned\n* Those who have experienced any alternative methods for preparing for birth or managing labor pain (such as yoga, meditation, breathing exercises, hypnosis)",true,"FEMALE","20 Years","35 Years",{"count":22,"type":23},90,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to investigate the effects of Binaural Beats-supported music and virtual reality experience on the levels of oxytocin, prolactin, catecholamine, endorphin, prostaglandin E and cortisol, which are hormones that play an active role in birth, using the Elisa method. Additionally, the study will examine the effects of virtual reality experience and Binaural Beats-supported music during labor on labor pain and some birth outcomes (such as the presence of an episiotomy, the onset of labor, the duration of labor, and the newborn Apgar score).The randomized controlled study will consist of three groups: a virtual reality group, a Binaural Beats-supported music group, and a control group. The research will be completed with a total of 90 people, with 30 people in each group. The research will be conducted at the Maternity Ward of Istanbul Gaziosmanpaşa Training and Research Hospital. Ethics committee approval has been received for the research. Data collection has not yet begun. An application has been made to the hospital administration for institutional permission. The research will begin once the permissions are received.",[29,30,31,32],"Birth","Hormones","Virtual Reality","Music",[29,34,35,36,37],"hormones","virtual reality","Binaural beats","music","NOT_YET_RECRUITING","2026-04-02",{"date":41,"type":42},"2026-04-08","ACTUAL",{"date":44,"type":23},"2026-05",{"date":46,"type":23},"2027-07",{"name":48,"class":49},"Medipol University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":81,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100629969","impact-of-training-load-on-the-gut-microbiome-and-its-relation-to-exercise-performance-muscle-phenotype-and-markers-of-overreaching-in-healthy-men-100629969","NCT07481578","Impact of Training Load on the Gut miCrobiome And Its Relation to exeRcise Performance, mUscle Phenotype, and markerS of Overreaching in Healthy Men","ICARUS: Impact of Training Load on the Gut Microbiome and Its Relation to Exercise Performance, Muscle Phenotype, and Markers of Overreaching in Healthy Men: Phase A - Human Trial","ICARUS","Inclusion criteria:\n\n* Males between 18 and 45 years old.\n* Recreationally active individuals, with a weekly exercise training volume between one and six hours per week.\n* Good health status confirmed by a sport medical screening, which includes a sport medical questionnaire and resting electrocardiogram.\n* Body Mass Index (BMI) between 18.5 and 27.5 kg\u002Fm².\n* Masters the Dutch language.\n\nExclusion criteria:\n\n* Engagement in strenuous competitive sports one month prior to or during the study intervention.\n* Medication and vaccination: Pro- or antibiotic treatment during the past three months, non-steroidal anti-inflammatory drugs (NSAIDs) or cholestyramine during the past month, drugs interfering with intestinal permeability (e.g., prokinetics, laxatives, lubiprostone, loperamide, anti-spasmodics, linaclotide, proton pump inhibitors) during the past month. Vaccinations within one month prior to or during the study intervention.\n* Blood donations within three months or plasma donation within one month prior to or during the study intervention.\n* Inflammatory bowel disease (Crohn or colitis ulcerosa) or celiac disease.\n* Diagnosed irritable bowel syndrome.\n* Intake of any performance-enhancing medication or nutritional supplements known to modulate the gut microbiome in the two months prior to or during the study.\n* Substance abuse, including alcohol consumption of more than three units\u002Fday (weekly average).\n* Any injury or pathology considered a contraindication for performing physical exercise, as determined by the medical doctor overseeing the preparticipation medical screening.\n* No access to smartphone and\u002For computer with internet access.\n* No willingness to use the Polar Flow app and MijnEetmeter to collect physical activity, heart rate, sleep, and food intake data.\n* Concomitant participation in another interventional trial, without approval from the research team.\n* Any other reasons considered by the research team that the participant will not complete the study.","MALE","18 Years","45 Years",{"count":63,"type":23},45,[26],"The goal of this study is to learn how different amounts of supervised indoor cycling training change gut health (gut bacteria, the substances gut bacteria make, and the gut barrier integrity), and how these changes relate to changes in fitness, muscle health, and signs of doing too much training (a state called 'overreaching'). The study includes healthy, recreationally active men aged 18 to 45 years.\n\nThe primary questions, for which the study is powered (sufficient participants included), are:\n\n1. Does moderate load training change blood and faecal levels of butyrate (a short-chain fatty acid made by gut bacteria) after eight weeks compared with a control group?\n2. Compared to moderate load training, do higher training loads lead to different responses in blood and faecal levels of butyrate?\n\nResearchers will compare:\n\n* A control group that does not complete structured training;\n* A moderate-load training group that completes eight weeks of supervised cycling (4x\u002Fweek);\n* A high-load training group that completes four weeks of moderate-load training followed by four weeks of higher training load (twice the number of training sessions).\n\nParticipants will:\n\n* Be randomly assigned to one of the three groups;\n* Complete 8 weeks of supervised indoor cycling sessions if assigned to a training group;\n* Complete four study assessment periods (baseline, after week four, after week eight, and after a short taper (rest period);\n* Provide blood, stool, skeletal muscle, urine, saliva, and breath samples during the assessment periods;\n* Complete fitness and performance tests and questionnaires during the assessment periods.",[67,68,69,70,71,72,73,30,74,75,76,77,78,79,80],"Exercise","Overreaching","Butyrate","Gut Microbiome","Exercise Performance","Skeletal Muscle","Glucose Tolerance","Vascular Health","Muscle Adaptation","Physical Fitness","Heart Rate Variability (HRV)","Anthropometric Measurements","Metabolic Health","Food Intake",[82,83,84,85,86,87,88,89,68,90,91,92,77,93,94,95],"Exercise training","Training load","Overload training","Fecal butyrate","Gut health","Exercise performance","Muscle phenotype","Physical fitness","Glucometabolic health","Vascular health","Muscle adaptation","Anthropometrics","Metabolic health","Food intake","RECRUITING","2026-03-16",{"date":99,"type":42},"2026-03-19",{"date":101,"type":42},"2024-10-07",{"date":103,"type":23},"2027-05-31",{"name":105,"class":49},"Stefan De Smet",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":60,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":136,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":50},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache","ALL","65 Years",{"count":116,"type":23},21,[26],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[120,121,122,123,124,125,126,127,128,129,130,30,131,132,133,134,135],"Headache Disorders, Secondary","Brain Diseases","Headache Disorders","Nervous System Diseases","Central Nervous System Diseases","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Pain","Peptide Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Peptides","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[137,129,134],"Post-traumatic headache","2026-01-05",{"date":140,"type":42},"2026-01-14",{"date":142,"type":23},"2026-02",{"date":144,"type":23},"2028-12",{"name":146,"class":49},"Danish Headache Center",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":113,"minAge":60,"maxAge":114,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":155,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":50},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":116,"type":23},[26],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[158,122,121,123,124,125,126,127,159,160,129,130,30,131,132,133,134,135],"Headache Disorders, Primary","Migraine Disorders","Headache",[162,160,129,134],"Migraine",{"date":140,"type":42},{"date":142,"type":23},{"date":166,"type":23},"2028-10-30",{"name":146,"class":49},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":20,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":183,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":50},"100603208","decision-making-and-food-intake-100603208","NCT07133529","Decision-making and Food Intake","Decision-making and Food Intake (\"Buffet Study\")","Buffet","Inclusion Criteria:\n\n* Nulliparous women (age: 18-35 years) with a regular menstrual cycle (25-32 days)\n* Legally competent\u002FConsent to participate\n* Language proficiency in German (native speaker, fluent)\n* Physically and mentally healthy\n* Body mass index (BMI) of 18.5 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Current or use of hormonal contraceptives in the previous 6 months\n* Current use of hormonal intra-uterine devices (IUDs)\n* Previous or current pregnancy\n* Diagnosed psychological or metabolic disorder\n* Former or current illnesses of:\n\n  1. Brain or mind (including anxiety disorders, depression, eating disorders, personality disorders, alcohol, drugs or drug or non-substance dependence, neurological disorders other than occasional headache, psychiatric or neurological abnomalities)\n  2. Heart or blood circulation\u002Fcardiovascular disease (myocardial infarction, stroke, hypertension, hypotension, having a pacemaker)\n  3. Gastro-intestinal disorders (e.g. colon diseases, irritable bowel syndrome, Crohn's disease)\n  4. Endocrine disorders (e.g. thyroid disorders)\n  5. Other serious past or present medical conditions (for example, metabolic syndrome, diabetes)\n* Other serious health problems or current severe mental or physical stress.\n* Blood clotting disorder\n* Fear of drawing blood\n* Severe anemia\n* Previously diagnosed hypoglycemia episodes\n* Regular intake of medication (e.g. Antidepressant\u002Fanti-anxiety medication)\n* Blood donation within 4 weeks before the study appointment\n* Intake of anticoagulant medications\n* illegal drug consumption\n* smoking or nicotine consumption\n* extreme athletes\n* vegetarians or vegans or any other dietary restrictions due to allergies or intolerances\n* shift workers",{"count":63,"type":23},[26],"The study will investigate how the expectation of food availability impacts the response to food cues, mood, interoceptive awareness, and consumption of food intake in healthy, naturally cycling women.",[180,30,181,182,80],"Behavior","Stress","Cognition",[184,95,185],"Decision-making","Food uncertainty","2025-08-18",{"date":188,"type":42},"2025-08-21",{"date":190,"type":42},"2025-08-04",{"date":192,"type":23},"2026-07-31",{"name":194,"class":49},"German Institute of Human Nutrition",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":17,"sex":113,"minAge":60,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":204,"phases":4,"briefSummary":205,"conditions":206,"keywords":217,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":233},"100589754","apple-health-study-100589754","NCT06958523","Apple Health Study","Inclusion Criteria:\n\n* Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico);\n* Live in the United States of America;\n* Have an iPhone;\n* Have installed Apple Research app on your iPhone;\n* Be comfortable communicating in written and spoken English;\n* Be willing and able to provide informed consent to participate in the Study.\n\nExclusion Criteria:\n\n* Share your iCloud account, iPhone, or devices that collect health data such as Apple Watch with anyone else, because it could result in sharing another person's health information with the Study, making it challenging for researchers to use your information.",{"count":202,"type":23},500000,"5 Years","OBSERVATIONAL","The Apple Health Study aims to build a diverse and inclusive group of participants to help researchers advance our understanding of how signals and information collected from apps and devices relate to health and may be used to predict, detect, monitor, and manage changes in health.\n\nTo enroll, US residents who have an iPhone can download the Apple Research app from the App Store and go through the introduction and informed consent for the Apple Health Study. This study is fully remote, and all are invited to enroll if the eligibility criteria are met.\n\nParticipants will be asked to complete tasks and surveys, using their iPhone and Apple Research app which include:\n\n* Selecting the types of data they would like to share with the study such as health and sensor data\n* Completing tasks and surveys including areas such as personal demographic information, personal medical history, family history, and social determinants of health",[207,208,67,30,79,209,210,211,212,213,214,215,216],"Mental Health","Sleep","Hearing","Aging","Lifestyle Factors","Functional Capacity","Neurological Conditions","General Health","Wellbeing","Women's Health",[199,218,219,220,221,222],"Large Scale Digital Study","Digital Biomarkers","Research App","Apple Research App","iPhone","2025-07-24",{"date":225,"type":42},"2025-07-29",{"date":227,"type":42},"2025-02-12",{"date":229,"type":23},"2030-02",{"name":231,"class":232},"Apple Inc.","INDUSTRY",2,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":24,"phases":244,"briefSummary":245,"conditions":246,"keywords":255,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":50},"100568305","impact-of-menstrual-cycle-based-resistance-training-on-neuromuscular-performance-in-female-athletes-100568305","NCT06679491","Impact of Menstrual Cycle-Based Resistance Training on Neuromuscular Performance in Female Athletes","Effects of Menstrual Cycle-based Undulating Periodized Resistance Training in Women's Neuromuscular Abilities","MENSES","Inclusion Criteria:\n\n* Female athletes with natural menstrual cycles (eumenorrheic): Participants must have regular menstrual cycles lasting between 21 and 35 days, with at least 9 cycles per year.\n* Women using a low-dose monophasic estrogen-progestin oral contraceptive.\n* Age 18 or older: Participants must be legal adults.\n* Body Mass Index (BMI) between 18 and 30 kg\u002Fm².\n* No medical contraindications to high-level physical training or exercise.\n* Physically active: Engages in at least 3 hours of physical activity per week.\n* Informed consent: Provides written, informed consent to participate in the study.\n* Affiliation with a social security system (if applicable by local regulations).\n\nExclusion Criteria:\n\n\\-",{"count":243,"type":23},60,[26],"The goal of this clinical trial is to assess the impact of menstrual cycle-based resistance training on neuromuscular function in female athletes.\n\nThe primary questions it aims to answer are :\n\n* Does varying resistance training intensity according to menstrual phases improve maximal knee extensor strength?\n* How do different training protocols affect voluntary activation, rate of force development, muscle stiffness, and vertical jump height?\n\nResearchers will compare natural menstrual cycle groups with an oral contraceptive control group to determine if menstrual phase-specific training influences neuromuscular adaptations.\n\nParticipants will:\n\n* Undergo 2 weekly resistance training sessions over 13 weeks with intensity adjustments based on menstrual phase\n* Complete periodic neuromuscular assessments across three menstrual phases: early follicular, late follicular, and mid-luteal before and after resistance training intervention",[247,248,249,250,251,252,253,30,254],"Menstrual Cycle","Resistance Training","Neuromuscular Function","Female Athlete","Women Health","Oral Contraceptive Pill","Muscle Strenght","Periodized Training",[247,256,257,258,259,30,260,261],"Resistance training","Periodized training","neuromuscular function","Female athlete","oral contraceptive pill","women health","2024-11-05",{"date":264,"type":42},"2024-11-07",{"date":266,"type":23},"2024-11-01",{"date":268,"type":23},"2027-12-31",{"name":270,"class":49},"Universite de La Reunion"]